Basal/HER2 breast carcinomas-Reference-Cited by-同舟云学术

Basal/HER2 breast carcinomas

Published:2013-01-15 Issue:2 Volume:12 Page:225-245
ISSN:1538-4101
Container-title:Cell Cycle
language:en
Short-container-title:Cell Cycle

Author:

Martin-Castillo Begoña,Oliveras-Ferraros Cristina,Vazquez-Martin Alejandro,Cufí Silvia,Moreno José Manuel,Corominas-Faja Bruna,Urruticoechea Ander,Martín Ángel G.,López-Bonet Eugeni,Menendez Javier A.

Publisher

Informa UK Limited

Subject

Cell Biology,Developmental Biology,Molecular Biology

Link

http://www.tandfonline.com/doi/pdf/10.4161/cc.23274

Reference178 articles.

1. Triple-negative breast cancer: disease entity or title of convenience?

2. Molecular portraits of human breast tumours

3. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

4. Repeated observation of breast tumor subtypes in independent gene expression data sets

5. Prognosis of Women With Metastatic Breast Cancer by HER2 Status and Trastuzumab Treatment: An Institutional-Based Review

Cited by 47 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. UGT1A7 altered HER2-positive breast cancer response to trastuzumab by affecting epithelial-to-mesenchymal transition: A potential biomarker to identify patients resistant to trastuzumab treatment;Cancer Gene Therapy;2024-08-10

2. UGT1A7 altered HER2-positive breast cancer response to trastuzumab by affecting epithelial-to-mesenchymal transition: A potential biomarker to identify patients resistant to trastuzumab treatment.;2024-03-07

3. Pyrotinib is effective in both trastuzumab-sensitive and primary resistant HER2-positive breast tumors;Chinese Journal of Cancer Research;2024

4. Pyrotinib-based therapeutic approaches for HER2-positive breast cancer: the time is now;Breast Cancer Research;2023-10-03

5. HER2-driven breast cancer suppression by the JNK signaling pathway;Proceedings of the National Academy of Sciences;2023-01-19